INTRODUCTION
Latent autoimmune diabetes of the adult (LADA) as originally described represents perhaps as many as 10 -20% of adult-onset patients with diabetes. 1 This slow autoimmune form of type 1 diabetes has been reported in the majority of Caucasian populations. [2] [3] [4] As far as we know, there is no report in the literature regarding LADA in a native Indian population from anywhere in the world. 5 We here report the first case of LADA in a Brazilian Indian.
We have prospectively evaluated all 15 diagnosed diabetic patients from a Brazilian Indian community composed of 1000 individuals (336 adults). The majority of these 15 patients are obese and all of them exhibited the clinical course of type 2 diabetes. 6 So far, they have been treated with diet and oral anti-diabetic agents.
CASE REPORT
We describe the case of a male 38-year-old Xavante-Jê Indian from the western groups of the Sangradouro community in Poxoréu, Mato Grosso, Brazil. About five years ago, he was diagnosed with diabetes symptoms (polyuria, polydipsia, polyphagia and weight loss) with a fasting plasma glucose (FPG) level of 22.2 mmol/L. After being treated with chlorpropamide for a period of 18 months, he started losing weight and presented with worsening of symptoms of diabetes followed by signs of ketosis. Insulin treatment was then initiated.
At this time arterial blood pressure (BP: 110 x 80 mmHg) or lipidemia (total cholesterol: 28.7 mmol/L and triglycerides: 1.16 nmol/L) were normal but he had a previous history of obesity (BMI > 27 Kg/m 2 ). Anti-GAD 65 was 4.1 U/ml (cut-off = 1.00 U/ml) using a radioimmunoassay kit with human recombinant I 125 GAD 65 from Kronus ® and IA-2 antibodies were 0.01 U/ml (cutoff = 0.47 U/ml) using a radioimmunoassay kit with human recombinant I There is a family history of diabetes that includes an obese sibling who has been treated with diet and oral anti-diabetic agent.
DISCUSSION
As is known, the usual features of LADA patients are: onset of diabetes at > 25 years of age, clinical presentation masquerading as type 2 diabetes, initial control of hyperglycemia with diet and oral anti-diabetic agents, evolution to insulin necessity within months and some features of type 1 diabetes such as low fasting C-peptide and positive anti-GAD antibodies. 7 Our patient shared all those characteristics (with age > 35 years at onset of diabetes, he had been non-ketotic and non-insulin dependent for 6 months and insulin deficiency was demonstrated by low serum fasting C-peptide).
Anti-GAD antibodies can be detected in about 10% of type 2 diabetic patients. 8 However this antibody is more frequent (73.7%) in these patients when they present LADA features. 9 The low prevalence of IA2 antibodies, as compared with anti-GAD, that has been shown in these patients, can help to explain the lack of 
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